Tu canal independiente de oncología en español
Regístrate aquí para recibir más contenidos
Registrarse
OncoBites te trae los resúmenes y
presentaciones más relevantes del congreso
ASCOGI 2026
Top resúmenes y presentaciones
Tislelizumab plus chemoradiotherapy (CRT) versus CRT or
chemotherapy (CT) as the neoadjuvant treatment for
patients (pts) with locally advanced
gastric/gastroesophageal junction adenocarcinoma
(GC/GEJC): A multicenter, randomized controlled,
open-label, phase IIb study (TERRIFIC).
286
Liposomal irinotecan, carboplatin or oxaliplatin (LyRICX)
with or without nivolumab in the first-line treatment of
metastatic or irresectable esophagogastric
adenocarcinoma: A randomized phase 2 study.
LBA287
Phase 2 ILUSTRO trial of 1L zolbetuximab plus mFOLFOX6 and
nivolumab in patients with CLDN18.2+ locally advanced (LA)
unresectable or metastatic gastric or gastroesophageal
junction (mG/GEJ) adenocarcinoma.
LBA284
CRITICS-II: A multicenter randomized phase II trial of
neo-adjuvant chemotherapy followed by surgery versus
neo-adjuvant chemotherapy and subsequent
chemoradiotherapy followed by surgery versus
neo-adjuvant chemoradiotherapy followed by surgery in
resectable gastric cancer.
283
Zanidatamab + chemotherapy (CT) ± tislelizumab for first-line
(1L) HER2-positive (HER2+) locally advanced, unresectable, or
metastatic gastroesophageal adenocarcinoma (mGEA):
Primary analysis from HERIZON-GEA-01.
LBA285
ASCOGI 2026
ESOFAGOGÁSTRICO
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse
Nivolumab plus ipilimumab vs lenvatinib or sorafenib as
first-line treatment for unresectable hepatocellular
carcinoma (HCC): 4-year follow-up of CheckMate 9DW.
LBA479
Results from the randomized phase 2 study (1801 Part 3B)
of elraglusib plus gemcitabine/nab-paclitaxel (GnP)
versus GnP in previously untreated metastatic pancreatic
ductal adenocarcinoma (mPDAC).
653
IKF-035/ABC-HCC: A phase IIIb, randomized, multicenter,
open-label trial of atezolizumab plus bevacizumab versus
transarterial chemoembolization (TACE) in
intermediate-stage hepatocellular carcinoma.
478
Integrated penpulimab (a PD-1 inhibitor), anlotinib (an
antiangiogenic targeted drug), nab-paclitaxel and
gemcitabine as first-line regimen for metastatic
pancreatic cancer: A multi-centered, randomized
controlled trial (RCT-PAAG).
655
A phase II study of re-introduction of gemcitabine plus
cisplatin in combination with durvalumab after
durvalumab maintenance therapy in patients with
unresectable or recurrent biliary tract cancer (PRIDE study).
TPS609
ASCOGI 2026
HEPATOBILIOPANCREÁTICOS
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse
Longitudinal study on the influence of physical activity in
managing cancer-related fatigue in patients with
colorectal cancer
16
Colorectal Cancer Metastatic dMMR Immunotherapy
(COMMIT) study: A randomized phase III study of
atezolizumab (atezo) monotherapy versus
mFOLFOX6/bevacizumab/atezo (FFX/bev) in the first-line
treatment of patients (pts) with deficient DNA mismatch
repair (dMMR) or microsatellite instability-high (MSI-H)
metastatic colorectal cancer (mCRC)—
NRG-GI004/SWOG-S1610.
14
GLP-1 receptor agonist vs aspirin for primary prevention of
colorectal cancer: Evidence from a real-world head-to-head
comparison
18
Diffusion-weighted magnetic resonance imaging versus
surgical staging in patients with colorectal peritoneal
metastases: The multicenter, international, randomized
controlled DISCO trial
15
BREAKWATER: Primary analysis of first-line (1L) encorafenib
+ cetuximab (EC) + FOLFIRI in BRAF V600E-mutant
metastatic colorectal cancer (mCRC)
13
ASCOGI 2026
COLORRECTAL
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse